Atea Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Atea Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Atea Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$37.2M, a 8.79% increase year-over-year.
  • Atea Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$200M, a 27.3% decline year-over-year.
  • Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$164M, a 25.7% decline from 2022.
  • Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$131M, a 194% decline from 2021.
  • Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was $138M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$164M -$33.5M -25.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$131M -$269M -194% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $138M +$149M Jan 1, 2021 Dec 31, 2021 10-K 2023-02-28
2020 -$11M +$3.58M +24.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$14.6M -$5.13M -54.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$9.48M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.